利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

241 条记录 (耗时 0.038 秒)

    ARTIFICIAL LYMPH NODE FOR TREATING CANCER
    64.
    发明申请
    ARTIFICIAL LYMPH NODE FOR TREATING CANCER 失效
    人工淋巴结肿瘤治疗癌症

    公开(公告)号：US20090263428A1

    公开(公告)日：2009-10-22

    申请号：US11939885

    申请日：2007-11-14

    申请人： Takeshi WATANABE ,  Kouji TANAKA

    发明人： Takeshi WATANABE ,  Kouji TANAKA

    IPC分类号： A61K39/00 ,  C12N5/06

    CPC分类号： A61K38/195 ,  A61K35/15 ,  A61K35/26 ,  A61K35/33 ,  A61K39/0011 ,  A61K2039/5152 ,  A61K2039/5158 ,  C12N5/065 ,  C12N2533/54 ,  A61K2300/00

    摘要： Provided is an artificial lymph node that is persistently effective in cancer treatment in vivo.A method of producing an artificial lymph node capable of inducing cancer antigen-specific immune responses, comprising the following steps: (a) a step for immunizing a non-human animal using a cancer antigen and an adjuvant capable of inducing cellular immunity; and (b) a step for transplanting an artificial lymph node material consisting of a polymeric biomaterial comprising cytokine-producing stromal cells and dendritic cells to the immunized non-human animal, an artificial lymph node capable of inducing cancer antigen-specific immune responses obtained by the method of production, a cancer therapeutic agent comprising the artificial lymph node, and a kit for producing an artificial lymph node for cancer treatment comprising the following: (a) a cancer antigen; (b) an adjuvant capable of inducing cellular immunity; (c) a cytokine expression vector and stromal cells, or stromal cells incorporating a cytokine expression vector; (d) dendritic cells; and (e) a polymeric biomaterial.

    摘要翻译： 提供了一种在体内持续有效的癌症治疗的人造淋巴结。 一种产生能够诱导癌症抗原特异性免疫应答的人造淋巴结的方法，包括以下步骤：（a）使用癌抗原和能诱导细胞免疫的佐剂免疫非人动物的步骤; 和（b）将由包含产生细胞因子的基质细胞和树突状细胞的聚合生物材料构成的人造淋巴结材料移植到免疫的非人动物的步骤，能够诱导由抗原特异性免疫应答获得的癌症抗原特异性免疫应答的人造淋巴结 生产方法，包含人造淋巴结的癌症治疗剂和用于制备用于癌症治疗的人造淋巴结的试剂盒，其包括：（a）癌症抗原; （b）能诱导细胞免疫的佐剂; （c）细胞因子表达载体和基质细胞或掺入细胞因子表达载体的基质细胞; （d）树突细胞; 和（e）聚合物生物材料。

    Proliferated cell lines and uses thereof
    67.
    发明申请
    Proliferated cell lines and uses thereof 有权
    增殖细胞系及其用途

    公开(公告)号：US20080175828A1

    公开(公告)日：2008-07-24

    申请号：US11981945

    申请日：2007-10-31

    申请人： Thomas B. Freeman ,  Pablo Caviedes ,  Raul Caviedes

    发明人： Thomas B. Freeman ,  Pablo Caviedes ,  Raul Caviedes

    IPC分类号： A61K35/12 ,  C07K14/00 ,  C12Q1/02 ,  A61P25/00 ,  A61P1/00 ,  C12N5/06

    CPC分类号： A61K35/26 ,  C12N5/0018 ,  C12N2500/84 ,  C12N2502/078 ,  C12N2502/30 ,  C12N2503/02

    摘要： The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferating cells in culture by containing cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non-fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation. The proliferated cells of the subject invention are useful for cell therapy, cell/gene therapy, biological production of molecules, and as in vitro models for research, toxicity testing, and drug development.

    摘要翻译： 本发明涉及可用于增加培养物中任何人或动物细胞的增殖潜力的肿瘤细胞系，从而提供永生化或连续的细胞系和培养物。 本发明还涉及增殖因子和含有因子的组合物，其能够增加培养物中任何人或其他动物细胞的增殖潜力。 本发明还涉及通过含有增殖因子的细胞来增殖培养细胞的方法。 增殖的细胞可以在可塑性范围内，并且可以包括例如胚细胞，受精卵，非受精配子，胚胎干细胞，成体干细胞，前体或祖细胞和高度专门的细胞。 任选地，可诱导细胞停止增殖。 本发明的增殖细胞可用于细胞治疗，细胞/基因治疗，分子的生物制备，以及用于研究，毒性测试和药物开发的体外模型。

    Process for Producing Engineered Targeted T Cell and Medicine
    68.
    发明申请
    Process for Producing Engineered Targeted T Cell and Medicine 有权
    生产工程靶向T细胞和药物的方法

    公开(公告)号：US20080019948A1

    公开(公告)日：2008-01-24

    申请号：US10583860

    申请日：2004-12-22

    申请人： Takashi Nishimura ,  Masaki Yasukawa

    发明人： Takashi Nishimura ,  Masaki Yasukawa

    IPC分类号： A61K35/00 ,  C12N5/06

    CPC分类号： A61K35/26 ,  A61K39/0011 ,  A61K39/395 ,  A61K2039/5156 ,  C07H21/04 ,  C12N5/0636 ,  C12N5/16 ,  C12N15/63 ,  C12N15/85

    摘要： A novel process for preparing tumor-specific T cells is disclosed. According to the invention, antitumor-active, tumor-specific T cells are prepared by transducing a TCR gene from a tumor-specific CTL into antitumor-active T cells that have been nonspecifically activated, thus enabling tumor-specific cellular immunotherapy to be carried out from even small amounts of blood. MHC class I-restricted, tumor-specific Th cells are obtained by the method, allowing for the production of cells that react with tumor cells expressing an MHC class I molecule and show a helper activity and an antitumor activity.

    摘要翻译： 公开了一种制备肿瘤特异性T细胞的新方法。 根据本发明，通过将来自肿瘤特异性CTL的TCR基因转导至非特异性激活的抗肿瘤活性T细胞来制备抗肿瘤活性的肿瘤特异性T细胞，从而能够进行肿瘤特异性细胞免疫治疗 从少量的血液。 通过该方法获得MHC I类限制性肿瘤特异性Th细胞，允许产生与表达MHC I类分子的肿瘤细胞反应并显示辅助活性和抗肿瘤活性的细胞。